Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilengitide + metronomic temozolomide in relapsed/refractory pediatric high-grade glioma or diffuse intrinsic pontine glioma
2009-011898-33Phase 2Completed
- Sponsor
- Martin Luther University Halle-Wittenberg
- Start
- Jun 2011
- Modality
- Modified Peptides → Peptides, Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cilengitide and temozolomide in glioma, diffuse intrinsic pontine glioma (DIPG) and anaplastic astrocytoma (AA), sponsored by Martin Luther University Halle-Wittenberg. Primary endpoint: 6-month overall survival rate after diagnosis of relapse or tumor progression. Started Jun 2011; status: completed.
02
Drugs
cilengitidetemozolomide
03
Conditions
gliomadiffuse intrinsic pontine glioma (DIPG)anaplastic astrocytoma (AA)
Beyond the preview
Go deeper on 2009-011898-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011898-33.